Biotech | February 27, 2022
VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Subscribe To Our Newsletter & Stay Updated
